Chester Kuei

Title: Chester Kuei: Innovator in Chimeric Peptide Research

Introduction

Chester Kuei is a prominent inventor based in San Diego, CA, known for his contributions to the field of chimeric peptides. With a total of 2 patents, Kuei has made significant strides in the development of high-affinity antagonists for G protein-coupled receptors.

Latest Patents

Kuei's latest patents include innovative research on chimeric polypeptides. One of his notable inventions is the "Chimeric peptide antagonist for GPCR135 or GPCR142," which describes the chimeric polypeptide R3(BΔ23-27)R/I5 as a high-affinity antagonist for GPCR135 and GPCR142 over LGR7. Another significant patent is "Relaxin-3 chimeric polypeptides and their preparation and use," which details chimeric polypeptides of relaxin-3, prepropolypeptides, polynucleotides encoding such polypeptides, and associated expression vectors and host cells. These polypeptides can be utilized to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be applied in various assay methods.

Career Highlights

Chester Kuei is currently associated with Janssen Pharmaceutica NV, where he continues to push the boundaries of peptide research. His work has garnered attention in the scientific community, contributing to advancements in therapeutic applications.

Collaborations

Kuei has collaborated with notable colleagues, including Changlu Liu and Steven W. Sutton, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Chester Kuei's innovative work in chimeric peptides and his contributions to the field exemplify the importance of research in advancing medical science. His patents reflect a commitment to developing new therapeutic strategies that could benefit many.